Cyclin-Dependent Kinase (CDK) Inhibitors Therapeutics Pipeline Projects Vast Growth Ahead     |    CAD Software Market to Reach $11,097 Million by 2023     |    Friedreich’s Ataxia (FRDA) Therapeutics Pipeline to Receive Various Drug Designations from the USFDA and EMA in the Coming Years
P&S Market Research - A market research firm

Press Journals

Chronic Obstructive Pulmonary Disease Pipeline to Witness Many Technological Advancements in the Coming Years

May 2017

According to a new research report “Chronic Obstructive Pulmonary Disease Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Chronic obstructive pulmonary disease currently exhibits a pipeline with 65 drug candidates.

Browse Report Overview at: https://www.psmarketresearch.com/market-analysis/copd-therapeutics-pipeline-analysis

Chronic obstructive pulmonary disease pipeline in 2017

The study analyzed that the chronic obstructive pulmonary disease pipeline comprises 65 drug candidates in different stages of development. Chronic obstructive pulmonary disease is a broad term used for progression of various other diseases that affect the lungs such as, emphysema, chronic bronchitis.


Insights on pipeline segments

As per the findings of the research, most of the drug candidates of chronic obstructive pulmonary disease pipeline are being developed to be administered by inhalation route.

Human combinatorial antibody library (HuCAL) technology platform for Chronic Obstructive Pulmonary Disease drug development

MorphoSys AG is using human combinatorial antibody library (HuCAL) technology platform for the development of their drug candidates in chronic obstructive pulmonary disease. The technology is used for the in vitro generation of highly specific and fully human antibodies.

Major companies collaborate for the development of Chronic Obstructive Pulmonary Disease Therapeutics Pipeline

The research found that various companies have collaborated for the development of chronic obstructive pulmonary disease therapeutics pipeline. In March 2017, Kyowa Hakko Kirin Co., Ltd. collaborated with AstraZeneca plc, had given the exclusive rights to AstraZeneca plc for benralizumab in Asia.

Some of the key players developing drugs for the treatment of chronic obstructive pulmonary disease include AstraZeneca plc, GlaxoSmithKline plc, Adamis Pharmaceuticals Corporation and others.

Chronic Obstructive Pulmonary Disease Therapeutics Pipeline Analysis

  • By Phase
  • By Route of Administration
  • By Molecule Type
  • By Company

Contact Us

  • U.S. Center : 347 5th Ave. #1402- 210 New York City, NY 10016 United States
  • Asian Address : B-28, Sector 1, Noida, U.P. - 201301 India.

Secure Online Payments

  • Payment